Video
Dr. Schmoll on the Objective of CHARTA for CRC
Author(s):
Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).
Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).
The CHARTA trial investigates the potential activity of FOLFOX plus bevacizumab (Avastin) with or without irinotecan, explains Schmoll. The primary endpoint of the study was the improvement of progression-free survival at 9 months.
Related Videos
Related Content
